Publications by authors named "I D Jenkins"
Chronic graft-versus-host disease (cGVHD) remains the leading cause of non-relapse morbidity and mortality after allogeneic hematopoietic cell transplantation (HCT). Effective therapeutics agents targeting dysregulated cytokines including IL-17 and CSF-1 have been defined in preclinical models of cGVHD, and efficacy in subsequent clinical trials has led to their recent FDA approval. Despite this, these agents are effective in only a subset of patients, expensive, difficult to access outside the US, and used in a trial-and-error fashion.
View Article and Find Full Text PDFArticle Synopsis
- After allogeneic hematopoietic cell transplantation (HCT), only a small fraction of donor stem cells help reconstitute the recipient's blood system, while the donor maintains a nearly normal stem cell pool.
- Researchers studied blood samples from 16 donor-recipient pairs, focusing on potential clonal hematopoiesis (CH) variants that could arise due to extra stress on donor cells post-transplant.
- Results showed similar mutation rates in both donors and recipients, with a small percentage of shared variants showing a significant increase in recipients over time, indicating that the human hematopoietic system has strong regenerative abilities even many years after HCT.
Article Synopsis
- Low bone mineral density is common in adults with sickle cell disease (SCD), and this study evaluated the impact of alendronate, a medication, on bone density in SCD patients with osteoporosis.
- Sixty-four adults with SCD participated, with results showing stable lumbar spine bone density after alendronate treatment, while side effects were mostly mild.
- The findings indicated that alendronate did not significantly alter bone density changes between genders, but those on treatment for over five years experienced a notable increase in lumbar spine bone density.
Background: Patients from socioeconomically disadvantaged backgrounds are underserved in randomised controlled trials, yet they experience a much greater burden of disease compared with patients from socioeconomically advantaged areas. It is crucial to make trials more inclusive to ensure that treatments and interventions are safe and effective in real-world contexts. Improving how information about trials is verbally communicated is an unexplored strategy to make trials more inclusive.
View Article and Find Full Text PDFBackground: The global incidence of type 2 diabetes (T2D) persists at epidemic proportions. Early diagnosis and/or preventive efforts are critical to attenuate the multi-systemic clinical manifestation and consequent healthcare burden. Despite enormous strides in the understanding of pathophysiology and on-going therapeutic development, effectiveness and access are persistent limitations.
View Article and Find Full Text PDF